Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donafenib - Suzhou Zelgen Biopharmaceuticals

Next Previous
X
Search
Drug Profile

Donafenib - Suzhou Zelgen Biopharmaceuticals

Alternative Names: CM 4307; Donafenib tosilate; Donafenib tosylate; Zeprosen®; Zeprosyn

Latest Information Update: 25 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Zelgen Biopharmaceuticals
  • Developer Peking Union Medical College Hospital; Suzhou Zelgen Biopharmaceuticals
  • Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Fluorinated hydrocarbons; Organic deuterium compounds; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Raf kinase inhibitors; Receptor protein-tyrosine kinase antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Liver cancer
  • Phase III Colorectal cancer; Thyroid cancer
  • Phase II Biliary cancer; Cervical cancer
  • Phase I/II Gastric cancer; Gastrointestinal cancer; Nasopharyngeal cancer; Oesophageal cancer; Solid tumours
  • No development reported Acute myeloid leukaemia; Non-small cell lung cancer

Most Recent Events

  • 22 Jul 2024 Tianjin Medical University Cancer Institute plans a phase II trial for Hepatocellular carcinoma in July 2024 (NCT06512467)
  • 31 May 2024 Updated efficacy and adverse events data from a phase I trial in Liver cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Pharmacodynamics data from a preclinical studies in Liver cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology, 2024 (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top